Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2012

01.10.2012 | Case Report

A case of ovarian mucinous adenocarcinoma in a premenarcheal girl

verfasst von: Yoko Matsushita, Yoshihito Yokoyama, Ryousuke Taniguchi, Kazuhiro Abe, Jun Watanabe, Hideki Mizunuma

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

We report a case of a 12-year-old premenarcheal girl who developed ovarian mucinous adenocarcinoma. The tumor, which originated from the right ovary, weighed 1400 g, and had a smooth surface and thin capsule, was extirpated. The cut surface showed multilocular cysts of various sizes and yellowish gelatinous to solid parts that accounted for approximately 40% of the cut surface. The histological findings showed a continuous mixture of mucinous adenoma, mucinous borderline tumor, and mucinous adenocarcinoma with an expansile invasive pattern. It was assumed that an ovarian mass developed in an early period after birth or infancy, and the mutation of certain oncogens occurred in an early period, leading to cancer. While some etiological hypotheses concerning ovarian carcinogenesis have been suggested, we believe this case provides valuable information when considering a new onset mechanism of ovarian epithelial malignant tumors.
Literatur
1.
Zurück zum Zitat Sri Paran T, Mortell A, Devaney D et al (2006) Mucinous cystadenoma of the ovary in perimenarchal girl. Pediatr Surg Int 22:224–227PubMedCrossRef Sri Paran T, Mortell A, Devaney D et al (2006) Mucinous cystadenoma of the ovary in perimenarchal girl. Pediatr Surg Int 22:224–227PubMedCrossRef
2.
Zurück zum Zitat Morowitz M, Huff D, von Allmen D (2003) Epithelial ovarian neoplasms in children: a retroperitoneal analysis. J Pediatr Surg 38:331–335PubMedCrossRef Morowitz M, Huff D, von Allmen D (2003) Epithelial ovarian neoplasms in children: a retroperitoneal analysis. J Pediatr Surg 38:331–335PubMedCrossRef
3.
Zurück zum Zitat Hernandez E, Rosenshein NB, Parmley TH (1982) Mucinous cystadenocarcinoma in a premenarchal girl. South Med J 75:1265–1267PubMedCrossRef Hernandez E, Rosenshein NB, Parmley TH (1982) Mucinous cystadenocarcinoma in a premenarchal girl. South Med J 75:1265–1267PubMedCrossRef
4.
Zurück zum Zitat Shankar KR, Wakhlu A, Kokai GK et al (2001) Ovarian adenocarcinoma in premenarchal girls. J Pediatr Surg 36:511–515PubMedCrossRef Shankar KR, Wakhlu A, Kokai GK et al (2001) Ovarian adenocarcinoma in premenarchal girls. J Pediatr Surg 36:511–515PubMedCrossRef
5.
Zurück zum Zitat Karaman A, Azili MN, Boduroglu EC et al (2008) A huge ovarian mucinous cystadenoma in a 14-year-old premenarchal girl: review on ovarian mucinous tumor in premenarchal girls. J Pediatr Adolesc Gynecol 21:41–44 Karaman A, Azili MN, Boduroglu EC et al (2008) A huge ovarian mucinous cystadenoma in a 14-year-old premenarchal girl: review on ovarian mucinous tumor in premenarchal girls. J Pediatr Adolesc Gynecol 21:41–44
6.
Zurück zum Zitat Center for Cancer Control and information Services. National Cancer Center, Japan. Cancer morbidity data according to the national estimate of the morbidity based on regional cancer registration (1975–2000): data source (National estimate of the morbidity based on regional cancer registration). http://www.ncc.go.jp/jp/cis/index.html Center for Cancer Control and information Services. National Cancer Center, Japan. Cancer morbidity data according to the national estimate of the morbidity based on regional cancer registration (1975–2000): data source (National estimate of the morbidity based on regional cancer registration). http://​www.​ncc.​go.​jp/​jp/​cis/​index.​html
7.
Zurück zum Zitat Lukanova A, Kaaks R (2005) Endogenous hormones and ovarian cancer: epidemiology and current hypothesis. Cancer Epidemiol Biomark Prev 14:98–107 Lukanova A, Kaaks R (2005) Endogenous hormones and ovarian cancer: epidemiology and current hypothesis. Cancer Epidemiol Biomark Prev 14:98–107
8.
Zurück zum Zitat Calle EE, Rodriguez C, Walker-Thurmond K et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRef Calle EE, Rodriguez C, Walker-Thurmond K et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRef
9.
Zurück zum Zitat Lacey JV Jr, Mink PJ, Lubin JH et al (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334–341PubMedCrossRef Lacey JV Jr, Mink PJ, Lubin JH et al (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334–341PubMedCrossRef
10.
Zurück zum Zitat Kurian AW, Balise RR, McGuire V et al (2005) Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 96:520–530PubMedCrossRef Kurian AW, Balise RR, McGuire V et al (2005) Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 96:520–530PubMedCrossRef
11.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRef Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10000 individuals. J Clin Oncol 20:1480–1490PubMedCrossRef
12.
Zurück zum Zitat Kobayashi H, Sumimoto K, Moniwa N et al (2007) Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17:37–43PubMedCrossRef Kobayashi H, Sumimoto K, Moniwa N et al (2007) Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 17:37–43PubMedCrossRef
13.
Zurück zum Zitat Konishi I, Kuroda H, Mandai M (1999) Review: gonadotropins and development of ovarian cancer. Oncology 57:45–48PubMedCrossRef Konishi I, Kuroda H, Mandai M (1999) Review: gonadotropins and development of ovarian cancer. Oncology 57:45–48PubMedCrossRef
14.
Zurück zum Zitat Beral V, Hermon C, Peto R et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314PubMedCrossRef Beral V, Hermon C, Peto R et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314PubMedCrossRef
15.
Zurück zum Zitat Hankinson SE, Hunter DJ, Colditz GA et al (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270:2813–2818PubMedCrossRef Hankinson SE, Hunter DJ, Colditz GA et al (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270:2813–2818PubMedCrossRef
16.
Zurück zum Zitat Chang ET, Lee VS, Canchola AJ et al (2007) Diet and risk of ovarian cancer in the California Teachers Study Cohort. Am J Epidemiol 165:802–813PubMedCrossRef Chang ET, Lee VS, Canchola AJ et al (2007) Diet and risk of ovarian cancer in the California Teachers Study Cohort. Am J Epidemiol 165:802–813PubMedCrossRef
17.
Zurück zum Zitat Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 17:163CrossRef Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 17:163CrossRef
18.
Zurück zum Zitat Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMed Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71:717–721PubMed
19.
Zurück zum Zitat Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467PubMedCrossRef Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467PubMedCrossRef
20.
Zurück zum Zitat Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443PubMedCrossRef Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433–443PubMedCrossRef
21.
Zurück zum Zitat Sato N, Tsunoda H, Nishida M et al (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in being endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrial carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052–7056PubMed Sato N, Tsunoda H, Nishida M et al (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in being endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrial carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052–7056PubMed
22.
Zurück zum Zitat Jiang X, Morland SJ, Hitchcock A et al (1998) Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58:1707–1712PubMed Jiang X, Morland SJ, Hitchcock A et al (1998) Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58:1707–1712PubMed
23.
Zurück zum Zitat Cuatrecasas M, Villanueva A, Matias-Guiu X et al (1997) K-ras mutations in ovarian mucinous tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79:1581–1586PubMedCrossRef Cuatrecasas M, Villanueva A, Matias-Guiu X et al (1997) K-ras mutations in ovarian mucinous tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79:1581–1586PubMedCrossRef
24.
Zurück zum Zitat Guan RJ, Fu Y, Holt PR et al (1999) Association of K-ras mutation with p16 methylation in human colon cancer. Gastroenterology 116:1063–1071PubMedCrossRef Guan RJ, Fu Y, Holt PR et al (1999) Association of K-ras mutation with p16 methylation in human colon cancer. Gastroenterology 116:1063–1071PubMedCrossRef
25.
Zurück zum Zitat Tannapfel A, Benicke M, Katalinic A et al (2000) Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47:721–727PubMedCrossRef Tannapfel A, Benicke M, Katalinic A et al (2000) Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47:721–727PubMedCrossRef
26.
Zurück zum Zitat Njim L, Moussa A, Saidani Z et al (2010) Bilateral ovarian serous borderline tumor with a giant non-invasive peritoneal implant in a four-year-old girl. J Pediatr Adolesc Gynecol 23:e1–e4PubMedCrossRef Njim L, Moussa A, Saidani Z et al (2010) Bilateral ovarian serous borderline tumor with a giant non-invasive peritoneal implant in a four-year-old girl. J Pediatr Adolesc Gynecol 23:e1–e4PubMedCrossRef
Metadaten
Titel
A case of ovarian mucinous adenocarcinoma in a premenarcheal girl
verfasst von
Yoko Matsushita
Yoshihito Yokoyama
Ryousuke Taniguchi
Kazuhiro Abe
Jun Watanabe
Hideki Mizunuma
Publikationsdatum
01.10.2012
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2012
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0333-0

Weitere Artikel der Ausgabe 5/2012

International Journal of Clinical Oncology 5/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.